Beneficial effects of pioglitazone on cognitive impairment in MPTP model of Parkinson's disease

被引:85
|
作者
Kumar, Pramod [1 ]
Kaundal, Ravinder K. [1 ]
More, Sandeep [1 ]
Sharma, Shyam S. [1 ]
机构
[1] NIPER, Mol Neuropharmacol Lab, Dept Pharmacol & Toxicol, Mohali 160062, Punjab, India
关键词
Cognition; Parkinson's disease; Dementia; Pioglitazone; 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Oxidative stress; Substantia nigra pars compacta; NIGRA PARS COMPACTA; GAMMA AGONIST PIOGLITAZONE; ACTIVATED-RECEPTOR-GAMMA; NF-KAPPA-B; SUBSTANTIA-NIGRA; DOPAMINERGIC-NEURONS; ALZHEIMERS-DISEASE; MEMORY IMPAIRMENT; LESIONED RATS; MOUSE MODEL;
D O I
10.1016/j.bbr.2008.10.010
中图分类号
B84 [心理学]; C [社会科学总论]; Q98 [人类学];
学科分类号
03 ; 0303 ; 030303 ; 04 ; 0402 ;
摘要
The present study was carried out to elucidate the beneficial effect of pioglitazone in cognitive impairment induced by bilateral infusion of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in substantia nigra pars compacta (SNc) in rats, a model of Parkinson's disease. MPTP-lesioned rats showed poor cognitive performance in both passive avoidance task and cued version of the Morris water maze test. This deficit in learning and memory was found to be associated with oxidative stress. Chronic administration of pioglitazone (10 and 30 mg/kg, p.o., starting 5 days prior to MPTP administration and then for next 30 days) in MPTP-lesioned rats improved cognitive performance in passive avoidance task and cued version of the Morris water maze test. Furthermore, pioglitazone treatment also reduced oxidative stress (as evident by reduced malondialdehyde and increased glutathione levels). These results demonstrate the beneficial effects of pioglitazone on cognitive impairment in MPTP induced Parkinson's disease in rats. (C) 2008 Elsevier B.V. All rights reserved.
引用
收藏
页码:398 / 403
页数:6
相关论文
共 50 条
  • [41] Mild cognitive impairment in Parkinson's disease
    Martinez-Horta, Saul
    Kulisevsky, Jaime
    JOURNAL OF NEURAL TRANSMISSION, 2019, 126 (07) : 897 - 904
  • [42] Approach to Cognitive Impairment in Parkinson’s Disease
    Qiang Zhang
    Georgina M. Aldridge
    Nandakumar S. Narayanan
    Steven W. Anderson
    Ergun Y. Uc
    Neurotherapeutics, 2020, 17 (4) : 1495 - 1510
  • [43] CERAD test performance and cognitive impairment in Parkinson's disease
    Karrasch, M.
    Laatu, S.
    Martikainen, K.
    Marttila, R.
    ACTA NEUROLOGICA SCANDINAVICA, 2013, 128 (06): : 409 - 413
  • [44] Cognitive impairment in nondemented Parkinson's disease
    Barone, Paolo
    Aarsland, Dag
    Burn, David
    Emre, Murat
    Kulisevsky, Jaime
    Weintraub, Daniel
    MOVEMENT DISORDERS, 2011, 26 (14) : 2483 - 2495
  • [45] Parkinson's Disease, Diabetes and Cognitive Impairment
    Ashraghi, Mohammad R.
    Pagano, Gennaro
    Polychronis, Sotirios
    Niccolini, Flavia
    Politis, Marios
    RECENT PATENTS ON ENDOCRINE METABOLIC & IMMUNE DRUG DISCOVERY, 2016, 10 (01) : 11 - 21
  • [46] Cognitive impairment in advanced Parkinson's disease
    Murakami, Takenobu
    Hanajima, Ritsuko
    NEUROLOGY AND CLINICAL NEUROSCIENCE, 2023, 11 (04): : 194 - 200
  • [47] Mild Cognitive Impairment in Parkinson's Disease
    Aarsland, Dag
    Bronnick, Kolbjorn
    Fladby, Tormod
    CURRENT NEUROLOGY AND NEUROSCIENCE REPORTS, 2011, 11 (04) : 371 - 378
  • [48] The Genetic Basis of Cognitive impairment and Dementia in Parkinson's Disease
    Collins, Lucy M.
    Williams-Gray, Caroline H.
    FRONTIERS IN PSYCHIATRY, 2016, 7
  • [49] Dementia and mild cognitive impairment in Parkinson's disease: a review
    Bocanegra, Yamile
    Trujillo-Orrego, Natalia
    Pineda, David
    REVISTA DE NEUROLOGIA, 2014, 59 (12) : 555 - U60
  • [50] Mild cognitive impairment in Parkinson's disease
    Adler, Charles H.
    PARKINSONISM & RELATED DISORDERS, 2009, 15 : S81 - S82